From the Chief Executive
This year’s winner of the National Press Club of Australia’s Health Journalist of the Year award is Sonya Pemberton for her documentary ‘Jabbed: Love, Fear and Vaccines’. Medicines Australia sponsors the Excellence in Health Journalism Awards, and a range of winners won awards in their respective categories. The Minister for Health, Peter Dutton, presented the overall award for a Health Journalist of the Year to Sonya at the
As the name suggests, the Excellence in Health Journalism Awards celebrate excellence in reporting on health issues by the media. There is a lot of reporting about health issues by journalists and the media – some of it good, some of it not. Good health reporting is balanced, informed and seeks to explain health issues…
News and Updates
Data newly released by the Organisation for Economic Cooperation and Development (OECD) reveals that Australia is not matching other industrialised countries in investing in medicines to treat disease.
The new OECD Health Data 2014 report shows that Australia’s public spending on pharmaceuticals is at 0.7 per cent of GDP, compared with the OECD average of 0.8 per cent, on the most recently available international data.
Medicines Australia Chief Executive, Dr Brendan Shaw, said these figures are very worrying.
Medicines Australia today applied for authorisation of the 18th Edition of its Code of Conduct to the Australian Competition and Consumer Commission.
“Medicines Australia’s member companies are taking the lead in setting new standards of transparency in Australia’s health sector with this new Code,” Medicines Australia Chief Executive, Dr Brendan Shaw, said.
“Interactions between healthcare professionals and pharmaceutical companies are essential for ensuring that patients have the best care. They ensure healthcare professionals have up to date and comprehensive information about medical developments.
New figures on the number of clinical trials demonstrate that reforms to improve the regulation of clinical trials are more important than ever.
Figures from the Therapeutic Goods Administration show that the number of clinical trials commenced in Australia fell by 10% in 2013. Since 2007 the number of new clinical trials conducted has fallen by 21%.
There was one bright spot in the latest numbers, with Phase I clinical trials conducted in Australia increasing by over 40% in 2013, compared to 2012. However, overall activity was down. The TGA’s latest Half-Yearly Performance Report shows 681 new pharmaceutical clinical trials were begun in Australia in 2013, down from 759 trials in 2012 – a fall of 10%.
Yet more price cuts announced yesterday to come into effect on 1 October for 300 medicines reaffirms that the Pharmaceutical Benefits Scheme is sustainable.
“We have been saying for a long time that these cuts will continue and, frankly, it’s no surprise. Some arguments that have been made about generic medicine pricing are clearly outdated,” Dr Brendan Shaw, Medicines Australia Chief Executive, said.
Generic medicines on the PBS will see price cuts of up to 62 per cent on October 1 when the first round of simplified price disclosure takes effect.